1393371-39-5

MHY908 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ that increases transcriptional activity of PPARα and PPARγ in a luciferase reporter assay in AC2F rat liver cells when used at a concentration of 5 μM. In vivo, MHY908 (3 mg/kg per day) reduces serum glucose, triglyceride, and insulin levels and improves hepatic steatosis by reducing hepatic triglyceride levels and lipid droplet accumulation in db/db mice and 20-month-old rats. It reduces peroxynitrite and COX-2 levels, reactive oxygen species (ROS) production, and Akt phosphorylation in isolated kidney from 20-month-old rats when administered at a dose of 3 mg/kg. MHY908 inhibits mushroom tyrosinase (IC₅₀ = 8.19 μM). It also inhibits increases in melanin content in α-melanocyte stimulating hormone-induced B16/F10 murine melanoma cells when used at a concentration of 10 μM.

MHY908 is a dual agonist of PPARα and PPARγ.

[1] MIN HI PARK. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.[J]. PLoS ONE, 2013: e78815. DOI: 10.1371/journal.pone.0078815
[2] MIN HI PARK. Effects of MHY908, a New Synthetic PPARα/γ Dual Agonist, on Inflammatory Responses and Insulin Resistance in Aged Rats.[J]. Journals of Gerontology Series A-Biological Sciences and Medical Sciences, 2016, 71 3: 300-309. DOI: 10.1093/gerona/glv043
[3] MIN HI PARK. Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908)[J]. Archives of Pharmacal Research, 2014, 38 4: 505-511. DOI: 10.1007/s12272-014-0532-0